Neurotrack, a US-based developer of digital medical tools for predicting cognition and memory loss, has received $21m in a series C round featuring insurance firms Dai-ichi Life and Sompo Holdings.
Venture capital firm Khosla Ventures led the round, which also included Sozo Ventures, Rethink Impact and AME Cloud Partners.
Founded in 2012, Neurotrack develops digital health applications that rely on eye-tracking technology to evaluate patients at risk of cognitive decline.
The capital will be used to develop Neurotrack’s strategy, product and partnerships, as it looks to build market adoption of its flagship tool, which helps predict Alzheimer’s disease.
The company has teamed up with Dai-ichi Life in Japan to enrol holders of Dai-ichi’s dementia insurance policy in its Alzheimer’s program. It has previously partnered Sompo to conduct pilot studies for its technology.
Neurotrack has now raised $51.2m altogether, including $13.7m in a March 2018 series B round led by Sozo Ventures that featured Khosla Ventures, Founders Fund, AME Cloud Ventures, Rethink Impact, Social Capital and private investor Marc Benioff.
The company had already received $9.9m in equity financing from undisclosed investors in May 2017, according to a regulatory filing.
Khosla Ventures had led a $6.5m round for Neurotrack the previous year that included Social Capital, Founders Fund, AME Cloud and iSeed Ventures.